Compare TEVA & FNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | FNV |
|---|---|---|
| Founded | 1901 | 1986 |
| Country | Israel | Canada |
| Employees | 32842 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9B | 43.6B |
| IPO Year | N/A | 2009 |
| Metric | TEVA | FNV |
|---|---|---|
| Price | $32.98 | $230.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $38.63 | ★ $248.13 |
| AVG Volume (30 Days) | ★ 4.7M | 903.6K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.69% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.98 |
| Revenue Next Year | $2.97 | $16.81 |
| P/E Ratio | ★ $28.19 | $53.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.99 | $152.89 |
| 52 Week High | $37.35 | $285.67 |
| Indicator | TEVA | FNV |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 53.61 |
| Support Level | $30.53 | $220.92 |
| Resistance Level | $35.37 | $241.86 |
| Average True Range (ATR) | 1.15 | 8.28 |
| MACD | -0.14 | 0.51 |
| Stochastic Oscillator | 18.99 | 72.19 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Franco-Nevada Corp is a precious-metals-focused royalty and investment company. The company owns a diversified portfolio of precious metals and royalty streams, which is actively managed to generate the bulk of its revenue from gold, silver, and platinum. The company does not operate mines, develop projects, or conduct exploration. The company's short-term financial performance is linked to the price of commodities and the amount of production from its portfolio of producing assets. Its long-term performance is affected by the availability of exploration and development capital. The company holds a portfolio of assets, diversified by commodity, revenue type, and stage of a project.